Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT5B | P51692 | 4/20 | 0.65 |
| ▸ | DHODH | Q02127 | 5/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096042 | 0.92 | STAT5B (0.54) | STAT5BDHODHDHFRPOLBPIM1 | |
| SCHEMBL22096043 | 0.86 | STAT5B (0.68) | STAT5BIDO1POLB | |
| SCHEMBL22096024 | 0.85 | STAT5B (0.79) | STAT5BPOLB | |
| SCHEMBL22096045 | 0.85 | STAT5B (0.61) | STAT5BDHODH | |
| SCHEMBL22096016 | 0.84 | STAT5B (0.81) | STAT5BPOLB | |
| SCHEMBL22096022 | 0.82 | STAT5B (0.81) | STAT5BPOLB | |
| SCHEMBL22096046 | 0.81 | STAT5B (0.42) | STAT5BPOLBPIM1PIM3PIM2 | |
| SCHEMBL22096040 | 0.80 | STAT5B (0.55) | STAT5BIDO1POLB | |
| SCHEMBL22096026 | 0.79 | STAT5B (1.00) | STAT5BIDO1 | |
| SCHEMBL22096017 | 0.78 | STAT5B (0.65) | STAT5BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FREIE UNIVERSITAET BERLIN (DE) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FLT3, MCL1, MYD88 | STAT5B 59/4885DHODH 84/4885DHFR 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.